30 years of historical data (1995–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Silence Therapeutics plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $257M | $106M | $215M | $164M | $708M | $600M | — | — | — | — | — |
| Enterprise Value | $94M | $-15144639 | $146M | $109M | $635M | $573M | — | — | — | — | — |
| P/E Ratio → | -1.71 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.42 | 2.45 | 8.46 | 7.56 | 57.06 | 109.45 | — | — | — | — | — |
| P/B Ratio | 0.47 | 0.79 | 9.77 | 7.41 | 83.08 | 66.20 | — | — | — | — | — |
| P/FCF | — | — | — | — | 95.91 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 77.11 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.35 | 5.77 | 5.05 | 51.14 | 104.50 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 85.97 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Silence Therapeutics plc earns an operating margin of -146.4%. Operating margins have expanded from -281.9% to -146.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -58.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.7% | 72.7% | 59.3% | 37.8% | 39.9% | 31.3% | 100.0% | — | -49543.8% | -1031.3% | — |
| Operating Margin | -146.4% | -146.4% | -195.5% | -281.9% | -369.0% | -654.3% | -9317.2% | — | -89943.8% | -1546.2% | — |
| Net Profit Margin | -104.7% | -104.7% | -170.5% | -232.4% | -317.4% | -594.0% | -8025.4% | — | -10112.5% | -1096.1% | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -58.1% | -196.4% | -329.0% | -448.2% | -217.2% | -70.0% | -42.1% | -3.0% | -14.7% | -15.1% |
| ROA | -28.1% | -28.1% | -38.1% | -49.4% | -43.3% | -49.3% | -46.1% | -39.2% | -2.9% | -14.4% | -14.6% |
| ROIC | -370.7% | -370.7% | — | — | — | — | -160.5% | -133.2% | -87.1% | -75.4% | -75.5% |
| ROCE | -44.8% | -44.8% | -54.3% | -73.3% | -64.8% | -74.0% | -63.6% | -47.1% | -27.0% | -20.8% | -22.2% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $121M exceeds total debt of $117000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.04 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.90 | -3.11 | -2.46 | -8.61 | -2.99 | -0.63 | -0.61 | -0.82 | -0.72 | -0.86 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -9.94 | — | -7.70 | — | — | — | — |
| Interest Coverage | — | — | -1458.94 | -1298.72 | -5726.75 | -2240.44 | -688.91 | — | -959.40 | — | — |
Net cash position: cash ($121M) exceeds total debt ($117000)
Short-term solvency ratios and asset-utilisation metrics
Silence Therapeutics plc's current ratio of 11.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.41x to 11.14x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.14 | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 7.70 | 17.14 | 26.09 | 47.90 |
| Quick Ratio | 11.14 | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 8.34 | 18.08 | 27.95 | 49.36 |
| Cash Ratio | 8.76 | 8.76 | 3.08 | 3.24 | 4.85 | 1.46 | 3.47 | 6.93 | 16.21 | 24.23 | 46.43 |
| Asset Turnover | — | 0.21 | 0.21 | 0.20 | 0.13 | 0.06 | 0.01 | — | 0.00 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 227.04 | 344.89 | 15.42 | 9.73 | 1952.31 | 5.98 | — | — | 383.96 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Silence Therapeutics plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 1.0% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $15M | $12M | $11M | $30M | $27M | $25M | $23M | $23M | $23M | $21M |
Compare SLN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SLNYou | $257M | -1.7 | — | — | 72.7% | -146.4% | -58.1% | -370.7% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SLN stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonSilence Therapeutics plc's current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
Silence Therapeutics plc's return on equity (ROE) is -58.1%. The historical average is -72.9%.
Based on historical data, Silence Therapeutics plc is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Silence Therapeutics plc has 72.7% gross margin and -146.4% operating margin.